Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results · Q4 FY26

Genomic Valley Biotech Q4 FY26 Results: Net Loss of ₹81,745 Cr, Loss Narrows

Genomic Valley Biotech Ltd reported revenue from operations of ₹375,000 Cr (-85.8% YoY) and a net loss of ₹81,745 Cr for Q4 FY26.

Q4 FY26 at a glance · ₹ crore
MetricQ4 FY26Q3 FY26Q4 FY25
Revenue from operations375000.0500000.02635094.0
Other income0.00.0676.0
Total income375000.0500000.02635770.0
Profit before exceptional items & tax15624.0105206.018548.0
Profit before tax15624.0105206.018548.0
Net profit-81745.0105206.0-834895.0
Operating margin4.2%21.0%0.7%

A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.

Growth
Revenue, year on year-85.80%
Source

BSE results filing, NSE: GVBL. Figures extracted from the filing.

Read the filing ↗

Genomic Valley Biotech Ltd: key numbers

Share price
₹27.65
Market cap
₹8.45 Cr
Revenue (annual)
₹0.27 Cr
Net profit (annual)
₹0.03 Cr
P/E (TTM)
415.2×Sector 50.4×
Promoter holding
46.06%+0.00% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Genomic Valley Biotech Ltd

All →